Contemporary themes in acute coronary syndrome management: From acute illness to secondary prevention

Medical Journal of Australia

Volumn 199, Issue 3, 2013, Pages 174-178

  Brieger, David B ^a,b   Redfern, Julie ^b,c  

^a ANZAC Research Institute   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; ARTICLE; AUSTRALIA; BLEEDING; CORONARY REPERFUSION; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART REHABILITATION; HUMAN; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THERAPY DELAY; THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; AUSTRALIA; CORONARY ANGIOGRAPHY; ELECTROCARDIOGRAPHY; EMERGENCIES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RISK ASSESSMENT; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; STENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84881274728     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.11224     Document Type: Article

References (48)

1. ACS in perspective: the importance of secondary prevention. Canberra: Deloitte Access Economics, 2011.
2. Briffa TG, Hobbs MS, Tonkin A, et al. Population trends of recurrent coronary heart disease event rates remain high. Circ Cardiovasc Qual Outcomes 2011; 4: 107-113.
3. Aliprandi-Costa B, Ranasinghe I, Chow V, et al. Management and outcomes of patients with acute coronary syndromes in Australia and New Zealand, 2000- 2007. Med J Aust 2011; 195: 116-121.
4. Redfern J, Maiorana A, Neubeck L, et al. Achieving coordinated secondary prevention of coronary heart disease for all in need (SPAN). Int J Cardiol 2011; 146: 1-3.
5. Australian Institute of Health and Welfare. Cardiovascular disease: Australian facts 2011. Canberra: AIHW, 2011. (AIHW Cat. No. CVD 53.)
6. White HD, Chew DP. Acute myocardial infarction. Lancet 2008; 372: 570-584.
7. Aroney CN, Aylward PE, Kelly AM, et al; Acute Coronary Syndrome Guidelines Working Group. Guidelines for the management of acute coronary syndromes 2006. Med J Aust 2006; 184 (8 Suppl): S1-S30.
8. Chew D P, Aroney CN, Aylward PE, et al. 2011 Addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes (ACS) 2006. Heart Lung Circ 2011; 20: 487-502.
9. Fox KA, Clayton TC, Damman P, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: a meta-analysis of individual patient data. J Am Coll Cardiol 2010; 55: 2435-2445.
10. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 360: 2165-2175.
11. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011; 377: 1409-1420.
12. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32: 1854-1864.
13. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-1476.
14. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.
15. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
16. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
17. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
18. Kloner RA, Schwartz Longacre L. State of the science of cardioprotection: challenges and opportunities - proceedings of the 2010 NHLBI Workshop on Cardioprotection. J Cardiovasc Pharmacol Ther 2011; 16: 223-232.
19. Vinten-Johansen J, Shi W. Perconditioning and postconditioning: current knowledge, knowledge gaps, barriers to adoption, and future directions. J Cardiovasc Pharmacol Ther 2011; 16: 260-266.
20. Song H, Song BW, Cha MJ, et al. Modification of mesenchymal stem cells for cardiac regeneration. Expert Opin Biol Ther 2010; 10: 309-319.
21. Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2012; (2): CD006536.
22. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Reducing risk in heart disease 2007 (updated 2008). Canberra: NHFA, 2008.
23. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297: 177-186.
24. Briffa TG, Kinsman L, Maiorana AJ, et al. An integrated and coordinated approach to preventing recurrent coronary heart disease events in Australia. Med J Aust 2009; 190: 683-686.
25. Redfern J, Ellis ER, Briffa T, Freedman SB. High risk-factor level and low risk-factor knowledge in patients not accessing cardiac rehabilitation after acute coronary syndrome. Med J Aust 2007; 186: 21-25.
26. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med 2005; 143: 659-672.
27. Huynh LT, Rankin JM, Tideman P, et al. Reperfusion therapy in the acute management of ST-segment-elevation myocardial infarction in Australia: findings from the ACACIA registry. Med J Aust 2010; 193: 496-501.
28. Richardson DB, Mountain D. Myths versus facts in emergency department overcrowding and hospital access block. Med J Aust 2009; 190: 369-374.
29. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med 2003; 163: 2345-2353.
30. Walters DL, Aroney CN, Chew DP, et al. Variations in the application of cardiac care in Australia. Med J Aust 2008; 188: 218-223.
31. Ranasinghe I, Alprandi-Costa B, Chow V, et al. Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. Am J Cardiol 2011; 108: 617-624.
32. Joynt KE, Huynh L, Amerena JV, et al. Impact of acute and chronic risk factors on use of evidence-based treatments in patients in Australia with acute coronary syndromes. Heart 2009; 95: 1442-1448.
33. Chew D P, Amerena JV, Coverdale SG, et al. Invasive management and late clinical outcomes in contemporary Australian man agemen t of acute coronary syndromes: observations from the ACACIA registry. Med J Aust 2008; 188: 691-697.
34. Heeley EL, Peiris DP, Patel AA, et al. Cardiovascular risk perception and evidence--practice gaps in Australian general practice (the AusHEART study). Med J Aust 2010; 192: 254-259.
35. Scott IA, Lindsay KA, Harden HE. Utilisation of outpatient cardiac rehabilitation in Queensland. Med J Aust 2003; 179: 341-345.
36. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e637S-e668S.
37. National Heart Foundation of Australia. Will you recognise your heart attack? Help your patients learn the warning signs of heart attack. http://www.heartfoundation.org.au/driving-change/warning-signs-heart-attack/Pages/professional-information.aspx (accessed Dec 2012).
38. Carstensen S, Nelson GC, Hansen PS, et al. Field triage to primary angioplasty combined with emergency department bypass reduces treatment delays and is associated with improved outcome. Eur Heart J 2007; 28: 2313-2319.
39. Hutchison AW, Malaiapan Y, Jarvie I, et al. Prehospital 12-lead ECG to triage ST-elevation myocardial infarction and emergency department activation of the infarct team significantly improves door-to-balloon times: ambulance Victoria and MonashHEART Acute Myocardial Infarction (MonAMI) 12-lead ECG project. Circ Cardiovasc Interv 2009; 2: 528-534.
40. Jollis JG, Al-Khalidi HR, Monk L, et al. Expansion of a regional ST-segment-elevation myocardial infarction system to an entire state. Circulation 2012; 126: 189-195.
41. Ranasinghe I, Turnbull F, Tonkin A, et al. Comparative effectiveness of population interventions to improve access to reperfusion for ST-segment-elevation myocardial infarction in Australia. Circ Cardiovasc Qual Outcomes 2012; 5: 429-436.
42. Peterson GM, Thompson A, Pulver LK, et al. Management of acute coronary syndromes at hospital discharge: do targeted educational interventions improve practice quality? J Healthc Qual 2012; 34: 26-34.
43. Curry LA, Spatz E, Cherlin E, et al. What distinguishes top-performing hospitals in acute myocardial infarction mortality rates? A qualitative study. Ann Intern Med 2011; 154: 384-390.
44. Wood DA, Kotseva K, Connolly S, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008; 371: 1999-2012.
45. Redfern J, Briffa T, Ellis E, Freedman SB. Patient-centered modular secondary prevention following acute coronary syndrome: a randomized controlled trial. J Cardiopulm Rehabil Prev 2008; 28: 107-115.
46. Vale MJ, Jelinek MV, Best JD, Santamaria JD. Coaching patients with coronary heart disease to achieve the target cholesterol: a method to bridge the gap between evidence-based medicine and the "real world" - randomized controlled trial. J Clin Epidemiol 2002; 55: 245-252.
47. National Heart Foundation of Australia. Secondary prevention of cardiovascular disease. Canberra: NHFA, 2010. http://www.heartfoundation.org.au/SiteCollectionDocuments/Secondary-Prevention-of-cardiovascular-disease.pdf (accessed Dec 2012).
48. Australian Commission on Safety and Quality in Health Care. Operating principles and technical standards for Australian clinical quality registries. Canberra: ACSQHC, 2008.